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Cancer cell of origin is difficult to identify by
analyzing cells within terminal stage tumors, whose
identity could be concealed by the acquired plas-
ticity. Thus, an ideal approach to identify the cell of
origin is to analyze proliferative abnormalities in
distinct lineages prior to malignancy. Here, we use
mosaic analysis with double markers (MADM) in
mice tomodel gliomagenesis by initiating concurrent
p53/Nf1 mutations sporadically in neural stem cells
(NSCs). Surprisingly, MADM-based lineage tracing
revealed significant aberrant growth prior to ma-
lignancy only in oligodendrocyte precursor cells
(OPCs), but not in any other NSC-derived lineages
or NSCs themselves. Upon tumor formation, pheno-
typic and transcriptome analyses of tumor cells re-
vealed salient OPC features. Finally, introducing the
same p53/Nf1 mutations directly into OPCs consis-
tently led to gliomagenesis. Our findings suggest
OPCs as the cell of origin in this model, even when
initial mutations occur in NSCs, and highlight the
importance of analyzing premalignant stages to
identify the cancer cell of origin.
INTRODUCTION
Cancer is a disease of genetic mosaicism because cancerous
cells harbor genetic mutations that are absent in normal cells
within the same individual. In familial cancer patients, even
though initial mutations exist in every cell, in most cases, only
specific cell types can progress into malignancy. Those cell
types are called cancer cell of origin. Such a cell type-specific
susceptibility implies the existence of a permissive or even syn-
ergizing signaling context in the cell of origin for particular
genetic mutations to cause cancer formation. Therefore, identi-fication of the cancer cell of origin would provide critical insights
for understanding tumorigenic mechanisms and for designing
rational therapeutic strategies.
Despite such importance, identification of the cell of origin for
most cancers has been a daunting task (Visvader, 2011). The reli-
ability of revealing cell identity solely based on molecular and
cellular analyses of late stage tumors is often confounded not
only by infiltrated bystander cells, but also by the acquired plas-
ticity often found in terminal cancerous cells. To circumvent
these issues, genetically engineered mouse models have been
widely used to determine the tumorigenic potential of a specific
cell type by initiatingmutationswith a cell type-specificCre trans-
gene. However, it is critical to note that cells initially acquiring
mutations (cell of mutation) may not be the cell of origin. When
mutations are introduced in stem/progenitor cells, it is extremely
difficult to distinguish whether initial mutant cells directly trans-
formorwhether theymerely pass onmutations tomore restricted
progeny that then transform. In the latter scenario, the mutated
stem/progenitor cell is simply the cell of mutation, and the trans-
forming progeny is the actual cell of origin (Visvader, 2011).
The cell of origin for malignant glioma, a type of deadly brain
cancer, remains controversial. Successful isolation of tumor
cells with stem cell features (known as cancer stem cells) from
human gliomas (Singh et al., 2004) implies neural stem cells
(NSCs) as the cell of origin. However, such NSC-like features
of malignant glioma cells could be acquired during transfor-
mation rather than reflect the nature of the original cell type (Vis-
vader, 2011). Further evidence supporting the NSC origin of
glioma was obtained from mouse genetic studies. For example,
the inactivation of tumor suppressor genes (TSGs) p53 and
neurofibromatosis 1 (NF1) or the expression of a mutant form
of p53 in NSCs consistently led to glioma formation in mouse
models, and the physical locations of tumors appeared to asso-
ciate with the subventricular zone (SVZ), where adult NSCs
reside (Alcantara Llaguno et al., 2009; Wang et al., 2009; Zhu
et al., 2005). However, other studies suggest that NSC-derived
progeny such as astrocytes or oligodendrocyte precursor cells
(OPCs) might directly transform (Bachoo et al., 2002; LindbergCell 146, 209–221, July 22, 2011 ª2011 Elsevier Inc. 209
Figure 1. MADM-Based Glioma Model Allows Phenotypic Analysis at Single-Cell Resolution
(A) Scheme of MADM-based glioma modeling. Inset illustrates how MADM concurrently mutates and labels cells (for full details, see Figure S1; Hippenmeyer
et al., 2010; Zong et al., 2005).
(B) Representative confocal images show hGFAP-Cre-induced MADM labeling of four NSC-derived cell types in a 2-month-old WT-MADMmouse. Arrows point
to MADM-labeled cells expressing corresponding markers. Scale bars, 20 mm; inset, 5 mm.
See also Figure S1.et al., 2009; Persson et al., 2010). This unresolved controversy
partially stems from the distinct oncogenic mutations used in
these models that make the direct comparison difficult and,
more importantly, from the lack of high-resolution analyses of
cellular aberrations during the transforming process.
Mosaic analysis with double markers (MADM), a mouse
genetic mosaic system (Zong et al., 2005), could, in principle,
be used to analyze aberrations in individual cell lineages prior
to the final transformation and should thus be suitable for identi-
fying cancer cell of origin. Via Cre/loxP-mediated mitotic inter-
chromosomal recombination, MADM generates a small number
of homozygousmutant cells, thusmimicking the sporadic loss of
heterozygosity (LOH) of TSGs in human cancers (Knudson,
1971). MADM also permanently labels these mutant cells with
green fluorescent protein (GFP) and their sibling wild-type (WT)
cells with red fluorescent protein (RFP) within an otherwise unla-
beled heterozygous mouse (Figure 1A and Figure S1A available
online). The single-cell resolution benefited from the sparse
labeling (0.1%–1% or much lower) (Zong et al., 2005) enables
one to track mutant cells throughout the entire process of tumor-210 Cell 146, 209–221, July 22, 2011 ª2011 Elsevier Inc.igenesis. The sibling red WT cells serve as internal controls for
green mutant cells, thereby greatly facilitating detailed analyses
of cellular aberrations of all lineages in their native environment.
In summary, MADM can provide features that are indispensable
for a robust analytical paradigm to identify a cell of origin.
Here, we report the application of MADM to glioma modeling.
After initiating p53/NF1 mutations sporadically in neural stem
cells (NSCs), we analyzed mutant NSCs and all of their progeny
at premalignant stages. We found dramatic overexpansion and
aberrant growth specifically in OPCs, but not in NSCs or other
lineages. Upon tumor formation, marker staining and transcrip-
tome analysis confirmed the OPC nature of tumor cells. Finally,
introducing the same mutations into OPCs consistently led to
gliomagenesis. Our findings reveal OPCs as the cell of origin
for glioma even when initial p53/NF1 mutations occur in NSCs,
thus resolving the current controversy by distinguishing cancer
cell of mutation from cell of origin. Importantly, although our
studies focused on glioma, the analytical paradigm with MADM
that is developed here could be applied to identify cellular origins
for many other cancers.
Figure 2. MADM-Mediated Sporadic Concurrent Inactivation of p53 and NF1 in Embryonic NSCs Reveals the Entire Process of Glioma-
genesis
(A) Sagittal sections from brains of MADMmice at indicated ages. InWT-MADMmice (left column), both green and red cells are WT. In mutant-MADMmice (right
column), green cells are p53 andNF1 double null; red cells, WT. Tumor boundary is demarcated with dashed line. Scale bars, 2 mm; insets, 100 mm. Ki67 staining
shows that tumor cells are highly proliferative.
(B) Systematic quantification of G/R ratios inmutant-MADMbrains fromP5 to P60. Total cell numbers counted are shown in parentheses. Each number is the sum
from three brains. Error bars represent standard error of the mean (SEM).
(C) The percentage of BrdU+ cells inWT andmutant cell populations in the brain parenchyma ofmutant-MADMmice at indicated ages. Error bars represent SEM.
(D) The proportion of BrdU+ cells with genotypes ‘‘/,’’ ‘‘+/,’’ and ‘‘+/+’’ in the brain parenchyma ofmutant-MADMmice at indicated ages. ‘‘+/’’ includes both
double-colored and colorless BrdU+ cells.
In (C) and (D), BrdU was administered 1.5 hr prior to sacrifice. Error bars ± SEM; n = 3 mice. See Experimental Procedures for sampling scheme. *p < 0.05,
**p < 0.01, paired t test.
See also Figure S2.RESULTS
Establishment of an MADM-Based Genetic Mosaic
Model for Glioma
MADM-based cancer modeling needs three prerequisites:
cancer-causing gene mutation(s), MADM cassettes that reside
centromerically to the prospective mutated genes, and a Cre
transgene that expresses in a certain tissue or organ. To estab-
lish an MADM-based glioma model, we decided to inactivate
p53 and NF1, both of which are among the most frequently
mutated genes in human glioma patients (McLendon et al.,
2008; Parsons et al., 2008) and have been used to model glioma
in mice (Reilly et al., 2000; Zhu et al., 2005). We also engineered
MADM cassettes into the Hipp11 genomic locus (Figure 1A and
Figures S1A and S1B) proximal to the p53 andNF1chromosomal
locations on mouse Chr. 11 (Hippenmeyer et al., 2010). To
induce MADM-based recombination, we chose hGFAP- orNestin-Cre transgenes (termed NSC-Cre hereafter) that are
expressed in both embryonic and adult NSCs (Petersen et al.,
2002; Zhuo et al., 2001), thereby generating MADM-labeled cells
in all NSCs-derived lineages: neurons, astrocytes, oligodendro-
cytes, and OPCs (Figure 1B). With the ability to identify MADM-
labeled cell types, we can readily analyze the aberrant growth
of GFP+ mutant cells by directly comparing to their RFP+ WT
counterparts within each lineage in the same mouse brain.
MADM-Based Glioma Model Offers the Opportunity
to Trace the Entire Tumorigenic Process
After recombining mutant alleles of p53 and NF1 with MADM
alleles to generate a mutant-MADM mouse model (Figure S1C),
we analyzed overall expansion of green mutant cells at different
ages. In contrast to the comparable distribution of green and red
cells in WT-MADM brains in which all labeled cells are wild-type
(Figure 2A, left), we observed a progressive overrepresentationCell 146, 209–221, July 22, 2011 ª2011 Elsevier Inc. 211
Figure 3. Analysis at a Pretransforming Stage of Gliomagenesis Suggests that OPCs Rather Than NSCs Serve as the Cell of Origin
(A) Average G/R ratios of each cell type in brain parenchyma of P60 mutant-MADMmice. *p < 0.05, **p < 0.01, paired t test. #p < 0.0001, one-way ANOVA. Error
bars represent SEM.
(B) (Left chart) With a single BrdU injection (1.5 hr prior to sacrifice) at P60, BrdU-positive mutant (/) cells in the brain parenchyma consist entirely of OPCs
(PDGFRa+). (Right chart) Upon BrdU administration by drinking water for 1 week, all BrdU-positive mutant (/) cells in the brain parenchyma belong to the
oligodendrocytic lineage (Olig2+), and the majority of them are OPCs (PDGFRa+).
(C–E) ‘‘4+1’’ channel staining shows that all BrdU+ mutant OPCs in a P60 mutant-MADM mouse brain belong to the oligodendrocyte lineage.
(C) Without Olig2 staining, all MADM-labeled BrdU+ cells are mutant (green). Notably, some BrdU+mutant cells are PDGFRa negative (marked with cyan circles).
(D) An adjacent section stained with Olig2 together withMADM, BrdU, and PDGFRa shows that all mutant BrdU+ cells have red nuclei, indicating positive staining
of Olig2.
(E) Representative magnified confocal images show: mutant cells without Olig2 staining (left), mutant cells with Olig2 staining in red channel (middle), and
heterozygous yellow cells (right). The orthogonal z axis is shown on the side of each panel. Scale bars: (C and D) 20 mm; insets, 5 mm; (E) 5 mm.
(F) G/R ratios of BrdU+ cells in the SVZ and NeuN+ cells in the olfactory bulb (OB) from P60 mutant-MADM mice. BrdU was given in drinking water for
7 days.
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of greenmutant cells in mutant-MADMbrains from postnatal day
5 (P5) to P60 (Figure 2A, top three of the right column) and even-
tually the formation of GFP+ full-blown tumors at 5 months of
age (Figure 2A, bottom-right).
Because mutant (green) and wild-type (red) sibling cells origi-
nate from the same mother cell in equal numbers initially (Fig-
ure 1A), the ratio of green to red cell numbers (referred to as
the G/R ratio hereafter) allows us to quantitatively evaluate the
extent of mutant cell expansion. A G/R ratio equal or close to 1
indicates no growth advantage of the mutant population,
whereas a G/R ratio > 1 indicates a growth advantage of mutant
over WT cells (referred to as ‘‘overexpansion’’ hereafter). From
P5 to P60, the average G/R ratio in mutant-MADM brains
increased from 4 to 30 (Figure 2B), indicating a continuous
overexpansion of mutant cells. However, the increase of G/R
ratio appeared to reach a plateau between P30 and P60, sug-
gesting that overexpansion of mutant cells had largely stopped
between those ages. In addition to quantifying cell numbers,
we also compared the proliferative status between mutant and
WT cells with a brief BrdU pulse to label cells undergoing DNA
replication. At all time points analyzed, the percentage of
BrdU+ cells in the mutant population was significantly higher
than that in theWT population (Figure 2C). Furthermore, whereas
WT cells largely ceased to proliferate at early postnatal age
(P10), somemutant cells (0.3% among all mutant cells popula-
tion) continued to divide and contributed to the entire population
of BrdU+ cells in the brain parenchyma at P60 (Figure 2D). Thus,
mutant cells showed not only elevated, but also prolonged prolif-
erative capacity compared to WT cells at a stage before tumor
formation (termed the ‘‘pretransforming’’ stage hereafter).
At later ages (4–5 months), all mutant-MADM mice developed
brain tumors with strong Ki67 staining (Figure 2A, bottom-right).
Tumors were invariably GFP+ (n = 28), indicating that they orig-
inated from MADM-induced mutant cells. Although trans-
criptome profiles of these tumors were very similar (see below),
pathological analysis revealed great heterogeneity in their
appearance: some showed typical astrocytic features; some
showed malignant glioma features such as necrosis, multinu-
clear giant cells, and perivascular and perineuronal satellitosis;
and most were highly anaplastic (Figure S2, Figures 4B–4D,
and Figure 5D). Taken together, MADM allows us to tracemutant
cells at all gliomagenic stages and provides the analytical acces-
sibility between initial mutations and the final transformation.
Mutant OPCs Manifest Dramatic Overexpansion
in Pretransforming MADM Brains
We next sought to determine the identity of glioma cell of origin
by separately determining the G/R ratio of NSCs and of each
NSC-derived cell type at P60, when mutant cell expansion had
largely ceased but tumors were yet to arise. We predicted that,
at this ostensibly dormant stage in tumorigenesis, the mutant
cell type capable of transformation should manifest significant
overexpansion and maintain sustained proliferative activity. We(G) Quantification of cells with indicated genotypes among all BrdU+ cells in the n
BrdU administration. n = 3mice for all quantification in (A), (B), (F) and (G). See Figu
schemes. Error bars represent ± SEM. Total cell numbers counted in (A), (B), (F),
See also Figure S3.first quantified the G/R ratios of all four NSC-derived cell types
(Figure 3A). The average G/R ratio from different brain regions
showed slight reduction of mutant neurons and only minor
expansion of mutant astrocytes and oligodendrocytes. In stark
contrast, the G/R ratio of OPCs was > 130, significantly higher
than those of the other three cell types (Figure 3A and Figure S3).
Notably, mutant OPCs appeared to have impaired differentiation
potentials to give rise to mature oligodendrocytes, as the G/R
ratio of oligodendrocytes was 10 times less than that of
OPCs (Figure 3A). Moreover, brief BrdU pulses at P60 exclu-
sively labeled mutant OPCs in brain parenchyma, although the
total number was low, suggesting that mutant OPCs were pro-
gressing but were still relatively dormant at this age (Figure 3B,
left). Remarkably, despite such a dramatic overrepresentation
of mutant OPCs, we did not observe any pathological features
in these brains by conventional pathological analysis (Table S2
and data not shown), demonstrating the capability of MADM to
probe into a previously inaccessible stage during tumor
development.
Mutant OPCsConstitute theMajority of the Proliferation
Pool in Pretransforming MADM Brains
It seems paradoxical that we found nearly full penetrance of
tumor formation in our model at 4–5 months of age (Table S2),
yet dividing cells at P60 were so rare (Figure 2C and Figure 3B,
left). Considering that pretransforming cells could undergo a
prolonged cell cycle, we evaluated the slow-dividing cell popula-
tion by extending the duration of BrdU administration and
observed that 30% of all mutant OPCs were able to incorporate
BrdU (Figure 3B, right, and data not shown), suggesting that
manymutant OPCswere dividing slowly. We noticed that a small
fraction of BrdU-positive mutant cells in the brain parenchyma
did not express the OPC marker PDGFRa (Figures 3B, right,
and 3C). To determine whether these were cells from other line-
ages or oligodendrocytes differentiated from recently divided
OPCs, we costained brain sections adjacent to those shown in
Figure 3C with antibodies against BrdU, PDGFRa, and Olig2,
a ‘‘pan-oligo’’ marker that expresses in bothOPCs and oligoden-
drocytes. Using a ‘‘4+1 channel’’ staining scheme (Figures
3C–3E), we found that all BrdU+, PDGFRa-negative cells exam-
ined expressed Olig2 (Figure 3D), suggesting that they were
newly differentiated oligodendrocytes from initially BrdU-labeled
mutant OPCs. Taken together, our detailed analysis reveals that,
among all mutant cell types, OPCs are the only proliferative
population in the brain parenchyma at pretransforming stages.
Although we did not observe the same extent of overexpan-
sion in other mutant cell types as that in mutant OPCs at P60,
it could be a result of increased cell death in neuronal and astro-
cytic lineage following the overexpansion of NSCs. Therefore, it
is critical to directly analyze the proliferative activity of adult
NSCs within the SVZ (Doetsch et al., 1999). After 7 days of
BrdU feeding of mutant-MADM mice, we quantified all BrdU+
cells in the SVZ, which include type B, C, and A cells (Doetschon-SVZ brain parenchyma (left chart) or the SVZ (right chart) after one week of
re S3 and Extended Experimental Procedures for detailed systematic sampling
and (G) are shown in parentheses. Each number is the sum from three brains.
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Figure 4. MADM-Generated Glioma Cells Exhibit Many OPC Features
(A) Representative image of a mutant-MADM brain carrying a GFP+ glioma.
(B–D) Adjacent H&E staining of tumor regions shows typical glioma features, including necrotic areas (‘‘N’’ in B), multinucleated giant cells (C), and perivascular
satellitosis (D). Scale bars: (A) 2 mm; (C and D) 200mm. Magnification in (B), 4003.
(E) Representative low-magnification images show elevated expression of a panel of well-established gliomamarkers in tumor regions. All staining was done with
adjacent sections from the same tumor. Tumor boundary is demarcated by dashed lines. T, tumor mass. Scale bars, 100 mm except for CD9 staining, for which it
is 50 mm.
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et al., 1999; also see Figure S6A). In stark contrast to our findings
in the brain parenchyma, where 85% of BrdU-positive cells were
mutant (Figure 3G, left), only 1% of BrdU-positive cells were
mutant in the SVZ (Figure 3G, right). More importantly, the G/R
ratio of BrdU+ cells in adult SVZ was not significantly different
from 1 (p = 0.39), indicating that there was no overexpansion
of mutant adult NSCs (Figure 3F). Furthermore, we did not
observe any overexpansion of mutant granule neurons in the
olfactory bulb, which are the main progeny generated by adult
NSCs (Figure 3F). Therefore, p53 and NF1 mutations seemed
unable to enhance the proliferative activity of adult NSCs. Taken
together, detailed comparison between mutant and WT cell
behaviors in NSCs and all progeny lineages strongly suggests
that NSCs function as the cell of mutation but fail to directly
transform, whereas OPCs function as the cell of origin for glioma.
Tumor Cells in Fully Developed Gliomas Exhibit Salient
OPC Features
Following the investigation at pretransforming stages, we next
analyzed the expression pattern of cell-specific markers in ma-
lignant tumors generated in the MADM-glioma model (Figures
4A–4D). Under low magnification, we observed prominent
enrichment of NSC markers Nestin and Sox2 and the astrocytic
marker GFAP, but not neuronal or oligodendrocyte markers in
the tumor region (Figure 4E). This observation is consistent
with previous findings in bothmousemodels and human patients
(Alcantara Llaguno et al., 2009; Louis et al., 2007; Wang et al.,
2009; Zhu et al., 2005) and has been considered as evidence
to support the NSC origin of gliomas. However, it is important
to note that these tumors also showed enriched expression of
OPC markers, such as Olig2, PDGFRa, NG2, CD9, and O4 (Fig-
ure 4E and data not shown). The expression of some OPC
markers was further confirmed by quantitative RT-PCR from
crude tumor samples (Figure 4F).
To clarify whether these markers were expressed by tumor or
bystander cells, we analyzed the tumor sections at highermagni-
fication and found that GFP+ proliferating tumor cells expressed
many markers for OPCs (Figure 4G-I), but not for neurons or
astrocytes (Figure 4J and 4K). In some tumors, there were
a few GFP+ cells expressing oligodendrocyte marker CC-1,
but not Ki67 (Figure 4L), which could be either residential cells
or oligodendrocytes differentiated from tumor cells. To extend
the molecular characterization of the cellular identity, we next
performed global transcriptome comparison between tumor
samples and all four neuroglial cell types (Cahoy et al., 2008)
and confirmed that tumor cells closely resembled OPCs, but
not any other neuroglial cell types (Figure 4M). Importantly,
regardless of diverse pathological features (Figure S2), all tumor(F) Quantitative RT-PCRs confirm the overexpression of OPC markers in MADM
(G–L) Confocal images at highmagnification show that proliferating (Ki67+) green
cell types (J–L). The signals of cell type marker staining in the right column of (J–L
Some Ki67-negative green cells were CC1+ (circled in L). Scale bars, 20 mm.
(M) Transcriptome comparison between tumor samples and four neuroglial cell t
(bottom four rows) with the single sample Gene Set Enrichment Analysis (ssGSEA
by NSC-Cre (Nestin-Cre or hGFAP-Cre) and by NG2-Cre, respectively. PDGFR
method. Red to blue indicates significantly similar to dissimilar.
See also Figure S4.samples shared almost identical molecular profiles (Figure 4M
and data not shown), suggesting a common cell of origin for
these morphologically heterogeneous tumors.
In line with immunofluorescent staining (Figure S2 and Fig-
ure 4E), we observed elevated Nestin level in some, but not all,
tumors by transcriptome and qRT-PCR analyses (data not
shown). However, it is unclear whether Nestin is expressed in
OPC-like tumor cells or in bystander cells. To clarify this
problem, we enriched for OPC-like tumor cells by using an im-
munopanning method widely used to purify WT OPCs based
on their surface expression of PDGFRa (Figures S4A–S4C)
(Cahoy et al., 2008). The transcriptome of purified OPC-like
tumor cells displayed an even higher extent of similarity to that
of normal OPCs (Figure 4M), demonstrating that these cells
contributed to the OPC signatures of glioma samples. qRT-
PCR results showed that, in addition to consistent expression
of OPC markers, purified OPC-like cells from some tumors ex-
pressed Nestin at a comparable level to NSC-derived neuro-
spheres (Figure S4D). This finding was further confirmed by
marker costaining of the tumor mass, showing that some
GFP+ dividing tumor cells coexpressed both PDGFRa and Nes-
tin (Figure S4E). Importantly, regardless of their Nestin expres-
sion levels, these panned tumor cells, when orthotopically allog-
rafted into NOD-SCID mouse brains, effectively initiated
secondary tumors (Figure S4F and Table S4) that recapitulated
both histological (Figures S4G–S4K) and molecular features
(Figures 4F and 4M and Figure S4D) of their primary tumors.
Taken together, these data demonstrate that highly proliferating
tumor cells manifested salient OPC features. Although Nestin
was expressed in some tumor cells, the fact that primary tumor
cells with either undetectable or high levels of Nestin expression
could efficiently initiate new tumors implies that Nestin expres-
sion appears irrelevant to tumorigenicity and is likely acquired
during transformation. Therefore, analyses of tumor cells further
support OPCs, rather than NSCs, neurons, or astrocytes, as the
cell of origin for glioma in p53, NF1 mutation-driven glioma
model.
Localization of Earliest Neoplastic Lesions Suggests
a Gray Matter Origin of Glioma
The analyses of lesion locations at early stages of transformation
could provide great insights for understanding the cancer cell of
origin. We first analyzed morphological or cyto-architectural
changes of mutant cells in fully developed tumors, reasoning
that some features could serve as landmarks of transformation,
thereby helping to determine the locations of early lesions. In
all malignant tumors, even in the smallest lesions identifiable
by classic pathology, MADM staining revealed a prominent-generated glioma.
tumor cells expressmarkers for OPCs (G–I, pointed by arrows), but not for other
) were converted to red for better examination of their colocalization with GFP.
ypes (top four rows) and the four subtypes of human GBMs defined by TCGA
) method. N andO represent tumor samples frommutant-MADMmice induced
a+ indicates primary tumor cells enriched by anti-PDGFRa immunopanning
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Figure 5. Spatial Analyses of Early Lesions Based on Perineuronal
Cytoarchitecture as a Landmark Implicate that Gliomas Initiate at
Brain Regions Away from the SVZ
(A–C) Immunofluorescent staining of mutant-MADM brains at distinct tumor-
igenic stages. Neuronal nuclei were stained with NeuN and are marked as ‘‘*.’’
Arrows point to perineuronal pretransforming OPCs or tumor cells. The
proliferating status of perineuronal mutant cells is shown by Ki67 staining
(yellow arrows in the bottom row).
(D) H&E staining of the adjacent section of (C) shows perineuronal satellitosis.
216 Cell 146, 209–221, July 22, 2011 ª2011 Elsevier Inc.cyto-architectural feature in whichmultiple glioma cells wrapped
around a single neuronal cell body (Figure 5C), a salient patho-
logical feature known as perineuronal satellitosis in human
glioma (Figure 5D). It should be noted that normal OPCs are often
juxtaposed to neuron cell bodies (Figure S5A), implicating that
perineuronal satellitosis in tumors might stem from this unique
cyto-architecture of OPCs.
When we compared OPC::neuron association from pretrans-
forming to tumor-bearing brains, we found that the number of
mutant OPCs for each accompanying neuron changes from
mostly one (occasionally two) prior to transformation (Figures
5A and 5E and Figure S5B) to frequently three or higher in any
Ki67-positive lesions (Figures 5B, 5C, and 5E). Therefore, we
used ‘‘three or more mutant OPCs per neuron’’ as a landmark
to examine a cohort of brains for initiating lesions that cover
a period from right after the dormant stage to around the time
when tumors can readily be identified (Figures 5F and 5G–5K).
In 2.5- to 3.5-month old mice, we observed the earliest detect-
able lesions in cortical gray matters (Figure 5F, P75–P90 and
top of P105 column). In further developed lesions, tumor cells
were more frequently found to overlap with white matter tracks
and the SVZ (Figure 5F, bottom of P105, P120, and > P120
columns). This observation indicates that previous findings of
glioma in white matter tracks and the SVZ (Persson et al.,
2010; Zhu et al., 2005) might be the path or endpoint, rather
than the starting point, of tumor cell migration and further argues
against NSCs and for OPCs as the cell of origin.
OPCs Can Be Directly Transformed into Malignant
Glioma by p53/NF1 Mutations
Our results thus far point toward the following scenario for glioma
development in our model: NSCs carrying p53/NF1 mutations
give rise to mutant OPCs, which multiply, progress, and eventu-
ally transform into malignancies. However, it remains unclear
whether mutations must occur in NSCs or whether OPCs can
be directly transformed by the same set ofmutations. To address
this question, we next used NG2-Cre that has been reported to
specifically express in OPCs, but not NSCs (Komitova et al.,
2009; Zhu et al., 2008), to perform MADM analysis. We first veri-
fied that NG2-Cre exclusively labels OPCs and oligodendro-
cytes, but not mature astrocytes or neurons in brain parenchyma
of WT-MADM mice (Figures 6A–6D). Next, we examined the(E) Proportion of perineuronal structures with distinct mutant OPC-to-neuron
ratios (O:N) either in pretransforming MADMmutant brains (P30 and P60, n = 3
brains each) or in tumors (T, n = 4).
(F) Schematic summary of lesion sites (green spots), which are defined by
O:N R 3 perineuronal structure together with MADM labeling, Ki67 staining,
and also pathology in most cases. Brains that are devoid of any detectable
lesions are shown in light gray. The analysis is based on a cohort of mutant-
MADM mice induced by hGFAP-Cre.
(G–K) Representative brain images from (F) with gliomas frommedium to small
sizes. Insets show Ki67 staining of the tumor regions. The glioma identity in
these brains was confirmed by pathological criteria except for (K), in which the
perineuronal structure ofR 3 mutant OPCs suggests that it should be a lesion
at its early stage.
Scale bars: (A–D) 20 mm; (G–K) left column, 2 mm; middle and right columns,
50 mm.
See also Figure S5.
Figure 6. OPCs Can Be Directly Transformed into Malignant Glioma
(A–D) In the MADM system, NG2-Cre transgene labels OPCs and oligoden-
drocytes, but not astrocytes or neurons. Arrows point to MADM-labeled cells
expressing indicated markers.
(E–H) Mutant OPCs overexpand at pretransforming stages. Brain sections
from P60 WT-MADM (E) or mutant-MADM (F) mice induced by NG2-Cre.
(G) G/R ratios within each cell lineage in P60 Mutant-MADM brains induced by
NG2-Cre. NA, not applicable. Error bars represent ± SEM. Total cell number
being counted is shown in parentheses.
(H) Percentage of OPCs (PDGFRa+) versus oligodendrocytes (CC1+) within
mutant and WT cell populations. n = 3 mice in (G) and (H). *p < 0.05, t test.
(I and J) Representative gross images ofmalignant glioma inNG2-Cre-induced
mutant-MADM mice, either locating around hypothalamus with invasion into
the subarachnoid space (I) or residing within the brain parenchyma (J). Arrowsentire SVZ of WT-MADM mice and never found any GFP- or
RFP-labeled cells coexpressing GFAP (Figures S6B and S6C).
Lastly, we thoroughly examined the olfactory bulbs (OB) from
fourWT-MADMmice and did not find any NeuN+MADM-labeled
green or red cells (Figures S6D and S6E), further supporting the
absence of NG2-Cre expression in NSCs.
In stark contrast to the extremely sparse labeling inWT-MADM
mouse brains induced by NG2-Cre (Figure 6E), the green mutant
OPCs in mutant-MADM mice populated the entire brain (Fig-
ure 6F) and reached an average G/R ratio of more than 300 (Fig-
ure 6G) at P60. Consistent with findings from the NSC-Cre-
based MADM model, the differentiation process of mutant
OPCs was hampered (Figures 6G and 6H). These data demon-
strate that introduction of NF1 and p53 gene mutations directly
into OPCs is sufficient to drive overproliferation and to impair
OPC differentiation.
After 8 months of age, we found GFP+ tumors in brains of
NG2-Cre-induced mutant-MADM mice at nearly full penetrance
(Figures 6I and 6J, Figure S7A, and Table S3). These tumors
showed marker staining and transcriptome profiles indistin-
guishable from NSC-Cre-induced malignant gliomas (Figures
S7C–S7H and Figures 4F and 4M). Dissociated cells from these
tumors could effectively initiate secondary tumors in allografting
assays (Figures S7B and S7I–S7N and Table S4), demonstrating
the malignancy of these OPC-initiated tumors.
Despite their indistinguishable marker expression patterns,
transcriptome profiles, and tumor-initiating ability, we observed
that tumors induced by NSC-Cre tended to reside in the brain
parenchyma, whereas those induced by NG2-Cre were more
frequently found around the ventral hypothalamic region and
often invaded into the subarachnoid space (Figure 6I, Figure 7B,
and Table S3). However, tumors induced by the two Cre lines at
equivalent locations showed indistinguishable pathological
features (Figures 7A and 7B). Moreover, although tumor cells
with subarachnoid invasion were morphologically distinct from
those in the brain parenchyma, transplanting them into the brain
parenchyma of NOD-SCID mice resulted in secondary tumors
that were morphologically indistinguishable from those primary
tumors in the brain parenchyma (Figure 7C). These data strongly
suggest that the variation in tumor pathology is merely an effect
of tumor location. The differences in latency and spatial distribu-
tion between NG2-Cre- and NSC-Cre-induced tumors most
likely are attributed to technical reasons, such as themuch lower
expression level ofNG2-Cre transgene or possible spatial biases
of these Cre lines. It is also possible that these two models have
distinct noncell-autonomous cues for tumor formation. For
instance, NSC-Cre generates heterozygous astrocytes or
neurons, whereas NG2-Cre does not, which might function as
special niches to facilitate tumor formation and to bias the tumor
location. Nevertheless, all lines of evidences, including marker
expression patterns (Figures 4F–4L and Figure S7), transcrip-
tome profiles (Figure 4M), tumorigenic capacity, and pathology
(Figure S4, Figure 7, and Figure S7), indicate that tumors fromin (I) point to tumor cells spreading along the meninges. Ki67 staining in insets
shows that tumor cells are highly proliferative. Scale bars, 2mm; inset, 100 mm.
See also Figure S6.
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Figure 7. Comparative Pathological Anal-
yses of NSC- and NG2-Cre Induced Tumors
Suggest that Tumor Cell Morphology Is
Highly Dependent on the Location Rather
Than Initially Mutated Cell Types
(A and B) Regardless of the Cre lines used, tumors
at the same location exhibit indistinguishable
pathological features.
(C) Transplantation of tumor cells from NG2-Cre-
induced glioma with subarachnoid invasion (top
row) into the brain parenchyma of NOD/SCID
mice to generate secondary tumors (bottom row).
Pathological features of the primary and the
secondary tumors mimic tumor features in (B) and
(A), respectively.
Tumor boundaries are demarcated by dashed
lines. The magnification of images in the middle
columns is 4003. Images from the right column
are 2.53 digital zoom-in of the corresponding
middle-column ones.both models are intrinsically identical. Therefore, our data
demonstrate that OPCs can be directly transformed into malig-
nant glioma as a result of concurrent p53/NF1 mutations.
Finally, we investigated the human relevance of our studies by
comparing the transcriptome profile of tumor cells in our model
with the molecular signatures of human glioma samples. Among
four subtypes of human malignant glioma revealed by recent
studies from the Cancer Genome Atlas (TCGA) (Verhaak et al.,
2010), both NSC-Cre- and NG2-Cre-initiated glioma models
match well with the proneural subtype (Figure 4M), which has
the poorest responses to chemo- and radiotherapies (Verhaak
et al., 2010). Therapeutic strategies designed according to the
intrinsic OPC nature should have promising effectiveness for
proneural or even other subtypes of glioma.
DISCUSSION
In this study, we used the mouse genetic mosaic system termed
MADM to track the entire tumorigenic process, with the aim of
identifying the cell of origin for glioma when initial concurrent
mutations of p53 and NF1 occur in embryonic NSCs. Taking
advantage of the in vivo cellular resolution and WT internal
control cells afforded by MADM, we analyzed lineage-specific
cellular aberrations at premalignant stages and observed218 Cell 146, 209–221, July 22, 2011 ª2011 Elsevier Inc.dramatic overexpansion and elevated
proliferative activity in the OPC lineage
but minimal abnormalities in NSCs and
all other progeny lineages. Furthermore,
marker staining, cyto-architecture, and
transcriptome analyses all point to
OPCs as the transforming cell type for
malignant glioma. Finally, direct introduc-
tion of p53/NF1 mutations into OPCs led
to the formation of glioma that were in-
distinguishable from those initiated from
NSCs, based on both transcriptome and
pathological analyses. Therefore, our
studies clarified that, for the gliomamodelinduced by p53 and NF1, though NSCs could serve as the
cell of mutation, OPCs serve as the actual cell of origin.
MADM as a Tool to Distinguish Cancer Cell of Origin
and Cell of Mutation
The identification of the cancer cell of origin is crucial but often
controversial, even with the use of genetic modified mouse
models (Visvader, 2011). Conceptually, caution must be taken
that cells acquiring initial mutations (cell of mutation) may not
directly transform into malignancy because their transforming
potential could be manifested by their progeny cell types. For
example, when Patched mutation was introduced into NSCs in
a mouse model of medulloblastoma, malignant transformation
only occurred after NSCs gave rise to lineage-restricted granular
neuron precursors (GNPs) (Schu¨ller et al., 2008; Yang et al.,
2008). In this scenario, the transforming potential of NSCs (cell
of mutation) is only manifested by mutant progeny GNPs, the
cell of origin that possesses the conducive signaling context.
Therefore, to unambiguously identify cancer cell of origin, one
has to genetically dissect the transforming potentials of all
progeny derived from the initial mutated cell type. This could
be feasible if highly specific Cre-transgenic lines are available,
such as in the case of medulloblastoma studies (Schu¨ller et al.,
2008; Yang et al., 2008). However, such a strategy cannot be
generalized to other cancer models due to the lack of specific
Cre-transgenic mice in every lineage for most tissues. An alter-
native approach is to analyze aberrant growth in all cell lineages
derived from initial mutant cells during pretransforming stages
(Visvader, 2011), which is now possible with MADM-based
cancer models.
Our study extends rather than contradicts previous reports.
Limited by the cellular resolution at pretransforming stages,
previous studies demonstrated the transforming potential of
NSCs but did not clearly distinguish cell of mutation from cell
of origin (Alcantara Llaguno et al., 2009; Wang et al., 2009; Zhu
et al., 2005). MADM, on the other hand, offers a robust analytical
paradigm for the identification of the cell of origin with both
permanently GFP-labeled mutant cells and RFP-labeled WT
internal control cells immediately after the initial mutations
occurred. In principle, MADM could be used for all types of
cancer, as long as oncogenic mutations for a particular type of
cancer, a tissue-specific stem cell Cre-transgenic line, and
cellular markers of each lineage within that tissue are available.
Our studies emphasize the importance of intersection
between genetic mutations and the signaling context within the
cell of origin. We show here that OPCs are particularly sensitive
to p53/NF1mutations, whereas NSCs and other brain cell types
are much less responsive. Interestingly, it has been reported that
the NF1mutation alone can promote OPCs to proliferate in mice
and zebrafish (Bennett et al., 2003; Lee et al., 2010), suggesting
that NF1 plays a pivotal role in regulating OPC proliferation with
conserved mechanisms across species. Such intersections
should be further exploited to help understanding of the molec-
ular mechanism of OPC transformation, which should provide
critical insights for developing effective therapeutic strategies.
Notably, whereas OPCs appear to be particularly responsive
to NF1 mutation, other cell types, including NSCs, could be
specifically vulnerable to other genetic lesions. It would be very
interesting to investigate whether different mutations could
transform distinct cell of origins, which might account for the
great heterogeneity of human glioma.
OPC Is an Important Glioma Cell of Origin with
Underappreciated Proliferative and Plastic Potentials
One of the notions that support the prevalent view of NSCs as the
glioma cell of origin is the persistent proliferative activity of NSCs
in the brain during the entire life, whichmakes themsusceptible to
oncogenic mutations. Additionally, NSCs share many cellular
properties with glioma cancer stem cells, such as the capability
to self-renew, the potential to differentiate into multiple cell line-
ages, and the expression of some common cellular markers
such as Nestin and Sox2. However, a large body of work has
revealed that many of these features are also shared by OPCs.
First, OPCs in fact represent the largest proliferative pool in the
brain parenchyma for both rodents and human (Dawson et al.,
2003; Geha et al., 2010). Second, OPCs at early developmental
stages have been found to express many commonly used stem
cell markers, including Nestin and Sox2. Third, OPCs isolated
from rat optic nerve can be readily reprogrammed into a multipo-
tent NSC-like status under in vitro conditions, which become self-
renewable and can differentiate into astrocytes and neurons in
addition to oligodendrocytes (Kondo andRaff, 2000). Intriguingly,OPCs from human subcortical white matter intrinsically behave
like NSCs without reprogramming (Nunes et al., 2003), raising
the possibility that primate OPCs are more plastic than their ro-
dent counterparts. Taken together, the intrinsic nature of OPCs
renders them great susceptibility to oncogenic mutations, which
could be harnessed to devise effective therapeutic strategies.
Previously, it has been reported that the injection of PDGF-BB-
expressing virus into the corpus callosum, the expression of
PDGF-BB under CNPase promoter, and the overexpression of
v-erbB under human S100b promoter all led to glioma formation
with OPC features (Assanah et al., 2006; Lindberg et al., 2009;
Persson et al., 2010). Although providing circumstantial evi-
dence, these studies have faced challenges to unequivocally
pinpoint OPCs as the cell of origin formalignant glioma (Visvader,
2011) due to noncell-autonomous effects caused by the secre-
tion of PDGF-BB (Assanah et al., 2006; Lindberg et al., 2009)
and the use of non-OPC-specific promoter to drive the initial
tumorigenic event (Persson et al., 2010). By circumventing all of
these caveats, our studies now firmly establish that OPCs serve
as the cell of origin for malignant glioma with relevant genetic
mutations. For clinical applications, intrinsic OPC properties
should be fully exploited to design effective therapies for glioma,
especially for theproneural subtype. For example, understanding
the unique proliferative capacity of OPCs could help devise
treatments to stall tumor progression; deciphering the migration
mechanism of OPCs could enhance the effectiveness of sur-
gery by preventing the infiltration of tumor cells into the entire
brain; and probing into the differentiation process of OPCs could
facilitate the design of differentiation therapy strategies.
The Application of MADM beyond Cancer Cell of Origin
Studies
Compared to conventional models, the MADM-based cancer
model bears significant advantages for exploring critical cancer
biology problems beyond the cell of origin. Its reliable labeling of
tumor cells at the single-cell resolution should help to distinguish
bona fide tumor cells from bystander cells in a complex tumor
mass, which is highly valuable for dissecting tumor architecture,
tracking metastasized tumor cells, and studying tumor-niche
interactions. Importantly, the availability of a built-in internal
control enables quantitative comparison between mutant and
WT sibling cells. Such rigorous phenotypic analyses within the
same animal largely remove variations often introduced by
comparing phenotypes between individual animals, thereby
helping to identify subtle but important phenotypes that could
be easily missed by using conventional approaches.
Using Drosophila genetic mosaic system, combined with the
application of positive marking with gene manipulation at the
mosaic level, helped to elucidate many fundamental questions
in cancer biology, such as identifying important oncogenes and
TSGs by forward genetic screening (Potter et al., 2001; Tapon
et al., 2001) and deciphering the complicated tumorigenic
processes such as metastasis (Pagliarini and Xu, 2003). Along
this same principle, we expect that a further modified MADM
system could address even more sophisticated problems in
cancer biology beyond the capability of the current one. For
instance, by replacing fluorescent reporters with a transcription
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expression inmosaicmutant cells, one couldmodel ‘‘second hit’’
events or therapeutic strategies and gain deep insights into the
molecular network for cancer formation. By incorporating novel
magnetic resonance imaging reporters such as H-ferritin (Gen-
ove et al., 2005) into MADM cassettes, one could noninvasively
trace tumor initiation, progression and metastasis in real time.
Also, by combining with transposon-based mutagenesis such
as Sleeping Beauty (Collier et al., 2005) or PiggyBac (Ding
et al., 2005), the MADM system should be able to perform
forward genetic screening for novel recessive TSGs in mouse
somatic cells without involving a large number of animals.
Concluding Remarks
In summary, our study demonstrates the importance of
analyzing the entire process of tumor development for identifying
cancer cell of origin. MADM-based tumor modeling can be
applied in principle to any other tumor type and should help to
resolve many important problems in cancer biology. Broadly,
the ability to perform sporadic single-cell genetic manipulations
in unambiguously labeled cells should make MADM an invalu-
able analytical tool for fields such as developmental biology
and neuroscience that rely heavily on in vivo analyses.
EXPERIMENTAL PROCEDURES
Mouse Lines and Genotyping Methods
All animal procedures were based on animal care guidelines approved by the
Institutional Animal Care and Use Committee. Mouse lines and genotyping
methods used in this study can be found in the Extended Experimental
Procedures.
Tissue Preparation and Histology
After anesthesia, mice were perfused with 4% ice-cold paraformaldehyde
(PFA) following the standard procedure. Brains were isolated, postfixed
(overnight at 4C), cryoprotected in 30% sucrose (overnight at 4C), and
embedded into optimal cutting temperature (O.C.T.) prior to cryosectioning
with a cryostat.
Imaging
All confocal images were collected by an Olympus FV-1000 upright laser
confocal microscope and analyzed with Fluoview 1000 software. Adobe
Photoshop CS3 was used for image processing.
Immunohistochemistry
Immunohistochemistry was performed using standard methodology. Details
about antibodies and working solutions can be found in the Extended
Experimental Procedures and Table S1.
Quantification
All quantification described in this work was performed based on the system-
atic sampling scheme described in the Extended Experimental Procedures
and Figure S3.
Purification of WT OPC and OPC-like Glioma Cells
WT OPCs from P8 cortical caps or OPC-like tumor cells from fresh glioma
samples were purified as previously described (Cahoy et al., 2008) with minor
modification. Detailed procedures can be found in the Extended Experimental
Procedures and Figure S4.
Tumor Cell Grafting
Tumor cells were suspended into Neurobasal medium with a density of 50,000
viable cells /ml. Tumor cell suspension (2–3 ml) was injected into right striata of
NOD-SCID mice (JAX laboratory) as previously described (Ligon et al., 2007).220 Cell 146, 209–221, July 22, 2011 ª2011 Elsevier Inc.Mice were monitored daily and sacrificed at the onset of neurological symp-
toms or once moribund or based on designed time point cohort.
Microarray and Gene Expression Analysis
44K Mouse Development Oligo Microarrays (Agilent Technologies) were used
for microarray analysis. Transcriptome comparison of tumor samples with WT
neuroglia cell types (Cahoy et al., 2008) or human GBM subtypes was pre-
formed as previously described (Verhaak et al., 2010). Array data are available
at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under the
accession number GSE26676. Detailed procedures are described in the
Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and four tables and can be foundwith this article online at doi:10.1016/
j.cell.2011.06.014.
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